Compounds > sulofenur
Page last updated: 2024-12-06

sulofenur

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

sulofenur: a diarylsulfonylurea [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID60417
CHEMBL ID7643
SCHEMBL ID4174
MeSH IDM0162382

Synonyms (44)

Synonym
NCI60_019612
NCI60_014449
ly-186641
n-(4-chlorophenylaminocarbonyl)indane-5-sulfonamide
n-(5-indansulfonyl)-n'-(4-chlorophenyl)urea
ly 186641
ly186641
1-(p-chlorophenyl)-3-(5-indanylsulfonyl)urea
1h-indene-5-sulfonamide, n-(((4-chlorophenyl)amino)carbonyl)-2,3-dihydro-
1h-indene-5-sulfonamide, 2,3-dihydro-n-(((4-chlorophenyl)amino)carbonyl)-
sulofenurum [inn-latin]
brn 4205979
nsc-642684
nsc642684
nsc-645012
nsc656667
sulofenur
nsc-656667
nsc645012
1-(4-chlorophenyl)-3-indan-5-ylsulfonyl-urea
n-(indanyl-5-sulfonyl)-n'-(4-chlorophenyl)urea
110311-27-8
sulofenur (usan/inn)
D05968
1-(4-chlorophenyl)-3-(2,3-dihydro-1h-inden-5-ylsulfonyl)urea
CHEMBL7643
unii-z45n070n3s
sulofenurum
z45n070n3s ,
sulofenur [usan:inn:ban]
SCHEMBL4174
sulofenur [mart.]
sulofenur [usan]
sulofenur [inn]
n-[[(4-chlorophenyl)amino]carbonyl]-indan-5-sulfonamide
n-([(4-chlorophenyl)amino]carbonyl)-2,3-dihydro-1h-indene-5-sulfonamide
JQJSFAJISYZPER-UHFFFAOYSA-N
nsc 642684; nsc 645012; nsc 656667
DTXSID20149208
BCP23826
ly186641; ly-186641; ly 186641
n-((4-chlorophenyl)carbamoyl)-2,3-dihydro-1h-indene-5-sulfonamide
oleylmyristate
Q27294971

Research Excerpts

Overview

Sulofenur is a novel diarylsulfonylurea with proven anti-tumor activity in murine tumor models. It is being tested in patients with advanced epithelial ovarian cancer refractory to standard chemotherapy.

ExcerptReferenceRelevance
"Sulofenur is a member of a new class of antineoplastic agents with a novel chemical structure and unique pharmacological and biological properties. "( Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer.
Einhorn, LH; Fossella, F; Lippman, SM; Munshi, NC; Seitz, DE, 1993)		2.06
"Sulofenur is a novel diarylsulfonylurea with proven anti-tumor activity in murine tumor models. "( A phase II study of sulofenur (LY186641) in gastric cancer.
Coleman, R; Hatty, S; Kamthan, A; Peters, B; Scarffe, JH; Smyth, JF; Walling, J, 1992)		2.05
"Sulofenur is a diarylsulfonylurea with demonstrated antitumor activity in patients with advanced epithelial ovarian cancer refractory to standard chemotherapy. "( Antitumor activity and clinical pharmacology of sulofenur in ovarian cancer.
Alberts, DS; Grindey, GB; Hamilton, M; Matzner, M; McCloskey, TM; Peng, YM; Plezia, PM; Roe, DJ; Seitz, D; Taylor, CW, 1992)		1.98

Effects

ExcerptReferenceRelevance
"Sulofenur has been evaluated in phase I and II trials in adults with a variety of solid tumors, but the toxicity and maximum tolerated dose of sulofenur in children and adolescents have not been determined."( A phase I study of sulofenur in refractory pediatric malignant solid tumors.
Avery, L; Bowman, LC; Luo, X; Marina, N; Meyer, WH; Pappo, A; Pratt, CB, 1995)		1.34

Treatment

ExcerptReferenceRelevance
"Sulofenur treatment (12.5 microM-1 mM) of colon adenocarcinoma cell lines resulted in dose- and time-dependent cell killing. "( Sulofenur cytotoxicity and changes in cytosolic calcium and mitochondrial membrane potential in human colon adenocarcinoma cell lines.
Berezesky, IK; Boder, GB; Jain, PT; Phelps, PC; Trump, BF, 1995)		3.18

Toxicity

ExcerptReferenceRelevance
" Both drugs were more toxic to the tumorigenic cells than to the normal cells, but LY295501 was significantly more toxic to both cells."( Studies on the mechanism of sulofenur and LY295501 toxicity: effect on the regulation of cytosolic calcium in relation to cytotoxicity in normal and tumorigenic rat kidney cell lines.
Berezesky, IK; Best, CJ; Boder, GB; Merriman, RL; Phelps, PC; Tanzer, LR; Trump, BF, 1995)		0.59
" No nucleosomal ladders were detected in quiescent cells during exposure to toxic concentrations of drug (IC90), or after removal of ISCU and addition of serum to stimulate growth."( Proliferation-dependent and -independent cytotoxicity by antitumor diarylsulfonylureas. Indication of multiple mechanisms of drug action.
Germain, GS; Harwood, FC; Houghton, PJ; Sosinski, J; Thakar, JH, 1993)		0.29

Pharmacokinetics

ExcerptReferenceRelevance
" In all species, sulofenur was well absorbed after an oral dose, but over a prolonged period, and sulofenur exhibited a fairly long half-life of elimination from plasma."( Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs.
Bewley, JR; Cornpropst, D; Ehlhardt, WJ; Grindey, GB; Hamilton, C; Hamilton, M; Sullivan, HR; Wood, PG; Woodland, JM; Worzalla, JF, 1993)		0.89

Bioavailability

Sulofenur (I) is well absorbed in both monkey and human. practically all of the excreted radiolabel from an oral dose is in the urine.

ExcerptReferenceRelevance
" Further studies that attempt to increase the bioavailability and improve the therapeutic index are warranted."( A phase II study of sulofenur, a novel sulfonylurea, in recurrent epithelial ovarian cancer.
Hardy, J; Hatty, S; O'Brien, ME; Peters, B; Tan, S; Walling, J; Wiltshaw, E, 1992)		0.61
" Sulofenur (I) is well absorbed in both monkey and human; practically all of the excreted radiolabel from an oral dose is in the urine."( Metabolism and disposition of the anticancer agent sulofenur in mouse, rat, monkey, and human.
Ehlhardt, WJ, )		1.29
" In all species, sulofenur was well absorbed after an oral dose, but over a prolonged period, and sulofenur exhibited a fairly long half-life of elimination from plasma."( Pharmacokinetics of the anticancer agent sulofenur in mice, rats, monkeys, and dogs.
Bewley, JR; Cornpropst, D; Ehlhardt, WJ; Grindey, GB; Hamilton, C; Hamilton, M; Sullivan, HR; Wood, PG; Woodland, JM; Worzalla, JF, 1993)		0.89

Dosage Studied

ExcerptRelevanceReference
" A maximum tolerated daily dosage was not defined, as methemoglobinemia was noted with each dosage level."( A phase I study of sulofenur in refractory pediatric malignant solid tumors.
Avery, L; Bowman, LC; Luo, X; Marina, N; Meyer, WH; Pappo, A; Pratt, CB, 1995)		0.62
" In conclusion although sulofenur had only minor side effects, in the dosage and schedule used, it did not produce any significant response in advanced non-small cell lung cancer."( Phase II study of sulofenur (LY 186641). A novel antineoplastic agent in advanced non-small cell lung cancer.
Einhorn, LH; Fossella, F; Lippman, SM; Munshi, NC; Seitz, DE, 1993)		0.93
" The dosage chosen on the basis of pre-clinical and phase I studies was 700 mg/m2 given orally once daily for 14 days, with treatments being repeated every 3 weeks."( Phase II trial of the novel sulphonylurea sulofenur in advanced breast cancer.
Button, D; Nicolson, MC; Powles, TJ; Smith, IE; Talbot, DC; Walling, J, 1993)		0.55
" In general, several analogs demonstrated excellent growth inhibitory activity in the 6C3HED model when dosed orally or intraperitoneally."( Sulfonimidamide analogs of oncolytic sulfonylureas.
Bewley, JR; Boder, GB; Ehlhardt, WJ; Gates, SB; Grindey, GB; Klingerman, KK; Ray, JE; Rinzel, SM; Schultz, RM; Toth, JE; Weir, LC; Worzalla, JF, 1997)		0.3
" The initial dosage was 250 mg/m2 escalating to 700 mg/m2 daily with no dose modification for the individual patient at any given dose level; 38 patients with advanced solid malignant tumours were enrolled."( Early clinical investigation of sulofenur with a daily schedule in advanced solid tumours.
Andersen, E; Andersen, H; Hansen, HH; Krarup-Hansen, A; Pedersen, H, 1997)		0.58
" Both types of assayed compounds, the N-(2-pyridylsulfonyl)urea and N-(2-pyridylsulfenyl)urea derivatives, inhibited by 50% the growth of the CCRF-CEM cell line at a dosage near to 1 microM."( Synthesis and cytotoxic activity of N-(2-pyridylsulfenyl)urea derivatives. A new class of potential antineoplastic agents.
Arteaga, C; Encío, I; Gil, MJ; González, A; Mañú, MA; Martínez-Merino, V; Migliaccio, M, 1999)		0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (46)

Assay IDTitleYearJournalArticle
AID103635Antitumor activity in vivo expressed as percent of inhibition in Lewis-lung carcinoma cell line1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID117211In vivo antitumor activity against subaxillary implanted 6C3HED lymphosarcoma implanted in C3H mice at a dose of 150 mg/kg administered perorally twice daily for a period of 8 days.1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Sulfonimidamide analogs of oncolytic sulfonylureas.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID43977Antitumor activity in vivo expressed as percent of inhibition in C3H-mammary adenocarcinoma cell line; 95-100% inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID8666Cytotoxicity against human lung carcinoma A549 cell line using MTT assay1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Synthesis and antitumor activity of 4-phenyl-1-arylsulfonyl imidazolidinones.
AID38317Antitumor activity in vivo expressed as percent of inhibition in B-16-melanoma (solid) cell line1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID111010Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Sulfonimidamide analogs of oncolytic sulfonylureas.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID153377Antitumor activity in vivo and the activity was determined as percent increase in life span determined against P388-lymphocytic leukemia tumor cell lines; 50-99 %1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID94802Cytotoxicity against human chronic myelogenous leukemia (K562) cell line using MTT assay1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Synthesis and antitumor activity of 4-phenyl-1-arylsulfonyl imidazolidinones.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID608341Anticancer activity against human KATO III cells by MTT assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Structure--activity relationship studies of novel arylsulfonylimidazolidinones for their anticancer activity.
AID608340Anticancer activity against human COLO205 cells by MTT assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Structure--activity relationship studies of novel arylsulfonylimidazolidinones for their anticancer activity.
AID106647Antitumor activity in vivo expressed as percent of inhibition in Madison-lung carcinoma cell line; 80-94% inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID608344Anticancer activity against mouse P388D1 cells by MTT assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Structure--activity relationship studies of novel arylsulfonylimidazolidinones for their anticancer activity.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID43703Cytotoxicity against CCRF-CEM lymphocytic leukemia cell line1999Bioorganic & medicinal chemistry letters, Aug-16, Volume: 9, Issue:16
Synthesis and cytotoxic activity of N-(2-pyridylsulfenyl)urea derivatives. A new class of potential antineoplastic agents.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID42420Antitumor activity in vivo expressed as percent of inhibition in CA-755-mammary adenocarcinoma tumor cell line; 95-100% inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID189673Hypoglycemic activity expressed as (Maximum reduction in blood glucose in mg/dL relative to predosing glucose level)/(time in hours at which maximum reduction occurred)1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID7270Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID202502Cytotoxicity against human ovarian adenocarcinoma (SK-OV-3) cell line using MTT assay1998Bioorganic & medicinal chemistry letters, Jun-16, Volume: 8, Issue:12
Synthesis and antitumor activity of 4-phenyl-1-arylsulfonyl imidazolidinones.
AID7290Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID103159Antitumor activity in vivo expressed as percent of inhibition in M-5-ovarian carcinoma cell line; 95-100% inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID44602Antitumor activity in vivo expressed as percent of inhibition in C-26-colon carcinoma cell line; 95-100% inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID608339Anticancer activity against human A549 cells by MTT assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Structure--activity relationship studies of novel arylsulfonylimidazolidinones for their anticancer activity.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID219580Antitumor activity in vivo expressed as percent of inhibition in X5563-plasma cell myeloma cell line; 60-79 % inhibition1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID25331Affinity constant was determined along with the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate)1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Sulfonimidamide analogs of oncolytic sulfonylureas.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID608343Anticancer activity against human SKOV3 cells by MTT assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Structure--activity relationship studies of novel arylsulfonylimidazolidinones for their anticancer activity.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID44016Concentration required to inhibit growth of CCRF-CEM cells in culture for 72 hr to 50% of control growth1990Journal of medicinal chemistry, Sep, Volume: 33, Issue:9
Novel agents effective against solid tumors: the diarylsulfonylureas. Synthesis, activities, and analysis of quantitative structure-activity relationships.
AID43708In vitro cytotoxicity against CCRF-CEM cells1997Journal of medicinal chemistry, Mar-14, Volume: 40, Issue:6
Sulfonimidamide analogs of oncolytic sulfonylureas.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID608342Anticancer activity against human K562 cells by MTT assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Structure--activity relationship studies of novel arylsulfonylimidazolidinones for their anticancer activity.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (51)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (9.80)18.7374
1990's36 (70.59)18.2507
2000's2 (3.92)29.6817
2010's2 (3.92)24.3611
2020's6 (11.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.36

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.36 (24.57)
Research Supply Index4.30 (2.92)
Research Growth Index5.49 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.36)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials15 (25.86%)5.53%
Reviews3 (5.17%)6.00%
Case Studies1 (1.72%)4.05%
Observational0 (0.00%)0.25%
Other39 (67.24%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
adenine
[no description available]		4.46116-aminopurines;
purine nucleobase		Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
verapamil
Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.		1.9810aromatic ether;
nitrile;
polyether;
tertiary amino compound
etanidazole
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.. etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.		3.0710C-nitro compound;
imidazoles;
monocarboxylic acid amide		alkylating agent;
antineoplastic agent;
prodrug;
radiosensitizing agent
carbonyl cyanide p-trifluoromethoxyphenylhydrazone
Carbonyl Cyanide p-Trifluoromethoxyphenylhydrazone: A proton ionophore that is commonly used as an uncoupling agent in biochemical studies.. carbonyl cyanide p-trifluoromethoxyphenylhydrazone : A hydrazone that is hydrazonomalononitrile in which one of the hydrazine hydrogens is substituted by a p-trifluoromethoxyphenyl group.		1.9710aromatic ether;
hydrazone;
nitrile;
organofluorine compound		ATP synthase inhibitor;
geroprotector;
ionophore
tolbutamide
Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.		1.9710N-sulfonylureahuman metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker
trimetrexate
Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.		5.3721
adenosine diphosphate
Adenosine Diphosphate: Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.		1.9710adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate		fundamental metabolite;
human metabolite
egtazic acid
Egtazic Acid: A chelating agent relatively more specific for calcium and less toxic than EDETIC ACID.. ethylene glycol bis(2-aminoethyl)tetraacetic acid : A diether that is ethylene glycol in which the hydrogens of the hydroxy groups have been replaced by 2-[bis(carboxymethyl)amino]ethyl group respectively.		1.9910diether;
tertiary amino compound;
tetracarboxylic acid		chelator
rotenone
Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.		1.9810organic heteropentacyclic compound;
rotenones		antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin
thiophenes
Thiophenes: A monocyclic heteroarene furan in which the oxygen atom is replaced by a sulfur.. thiophenes : Compounds containing at least one thiophene ring.		1.9810mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound		non-polar solvent
quinazolines
Quinazolines: A group of aromatic heterocyclic compounds that contain a bicyclic structure with two fused six-membered aromatic rings, a benzene ring and a pyrimidine ring.. quinazoline : A mancude organic heterobicyclic parent that is naphthalene in which the carbon atoms at positions 1 and 3 have been replaced by nitrogen atoms.. quinazolines : Any organic heterobicyclic compound based on a quinazoline skeleton and its substituted derivatives.		4.4611azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines
azacitidine
Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.		3.0710N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
azomycin
azomycin: RN given refers to parent cpd with specified locant; structure		3.0710C-nitro compound;
imidazoles		antitubercular agent
acetylcysteine
N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.		2.0110acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid		antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary
tolcyclamide
[no description available]		1.9710sulfonamide
deoxycytidine
[no description available]		3.4820pyrimidine 2'-deoxyribonucleosideEscherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
camptothecin
NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source		4.4611delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol		antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite
fludarabine phosphate
fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.		3.0710nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate		antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug
vidarabine phosphate
Vidarabine Phosphate: An adenosine monophosphate analog in which ribose is replaced by an arabinose moiety. It is the monophosphate ester of VIDARABINE with antiviral and possibly antineoplastic properties.		3.0710
4-ipomeanol
4-ipomeanol: lung-toxic furanoterpenoid produced in moldy sweet potatoes in response to fungus infection; RN given refers to cpd without isomeric designation; structure		4.4611aromatic ketone
paclitaxel
Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).		5.3721taxane diterpenoid;
tetracyclic diterpenoid		antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent
diflubenzuron
Diflubenzuron: An insect growth regulator which interferes with the formation of the insect cuticle. It is effective in the control of mosquitoes and flies.. diflubenzuron : A benzoylurea insecticide that is urea in which a hydrogen attached to one of the nitrogens is replaced by a 4-chlorophenyl group, and a hydrogen attached to the other nitrogen is replaced bgy a 2,6-difluorobenzoyl group.		1.9710benzoylurea insecticide;
monochlorobenzenes		insect sterilant
ribavirin
Rebetron: Rebetron is tradename		3.07101-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide		anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
epirubicin
Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.		3.0710aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone		antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
idarubicin
Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.		3.0710anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative
fazarabine
fazarabine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-arabinofuranosyl residue via an N-glycosidic linkage. A synthetic analogue of cytosine arabinoside and 5-azacytidine that incorporates structural features of both compounds, it shows good activity against a variety of transplanted tumors.		3.0710N-glycosyl-1,3,5-triazine;
nucleoside analogue		antineoplastic agent
amonafide
xanafide: salt formulation of amonafide; DNA-intercalating agent and topoisomerase II inhibitor		4.4611isoquinolines
gusperimus
gusperimus: synthesized by chemical modification of spergualin; in combination with cyclosporin A prevents diabetes in predisposed NOD mice; structure given in first source; RN given refers to (-)-isomer trihydrochloride		3.0710N-acyl-amino acid
flavone acetic acid
flavone acetic acid: structure given in first source		3.4820
brequinar
brequinar : A quinolinemonocarboxylic acid that is quinoline substituted by 2'-fluoro[1,1'-biphenyl]-4-yl, methyl, carboxy and fluoro groups at positions 2, 3, 4, and 6, respectively. It is an inhibitor of dihydroorotate dehydrogenase, an enzyme that is required for de novo pyrimidine biosynthesis. The compound exhibits antineoplastic and antiviral properties.		5.3721biphenyls;
monocarboxylic acid;
monofluorobenzenes;
quinolinemonocarboxylic acid		anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
EC 1.3.5.2 [dihydroorotate dehydrogenase (quinone)] inhibitor;
immunosuppressive agent;
pyrimidine synthesis inhibitor
crisnatol
crisnatol: structure given in first source		3.0710
piroxantrone
[no description available]		4.4611
gemcitabine
gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.		3.4820organofluorine compound;
pyrimidine 2'-deoxyribonucleoside		antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic
irinotecan
[no description available]		4.4611carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound		antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug
naphthalimides
Naphthalimides: Compounds with three fused rings that appear like a naphthalene fused to piperidone or like a benz(de)isoquinoline-1,3-dione (not to be confused with BENZYLISOQUINOLINES which have a methyl separating the naphthyl from the benzyl rings). Members are CYTOTOXINS.		4.4611
cyanates
Cyanates: Organic salts of cyanic acid containing the -OCN radical.. cyanates : Salts and esters of cyanic acid, HOC#N; compounds carrying the cyanate functional group -O-C#N.. isocyanates : Organonitrogen compounds that are derivatives of isocyanic acid; compounds containing the isocyanate functional group -N=C=O (as opposed to the cyanate group, -O-C#N).		2.0110
n-(5-(2,3-dihydrobenzofuryl)sulfonyl)-n'-(3,4-dichlorophenyl)urea
N-(5-(2,3-dihydrobenzofuryl)sulfonyl)-N'-(3,4-dichlorophenyl)urea: a second generation diarylsulfonylurea; structure given in first source		440
ly 181984
[no description available]		2.8940
organophosphonates
hydrogenphosphite : A divalent inorganic anion resulting from the removal of a proton from two of the hydroxy groups of phosphorous acid.		4.4611divalent inorganic anion;
phosphite ion
nogalamycin
Nogalamycin: An anthrocycline from a Streptomyces nogalater variant. It is a cytolytic antineoplastic that inhibits DNA-dependent RNA synthesis by binding to DNA.. nogalamycin : An anthracycline antibiotic isolated from Streptomyces nogalater. It is a DNA intercalator and exhibits anticancer properties.		3.0710
benzofurans
Benzofurans: Compounds that contain a BENZENE ring fused to a furan ring.		3.7830
menogaril
Menogaril: A semisynthetic anthracycline with the amino sugar on the D ring. It displays broad-spectrum antineoplastic activity against a variety of tumors.		3.0710
pentostatin
Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.		3.0710coformycinsantimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor
tiazofurin
tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).		3.07101,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide		antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug
rhodamine 123
Rhodamine 123: A fluorescent probe with low toxicity which is a potent substrate for ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 and the bacterial multidrug efflux transporter. It is used to assess mitochondrial bioenergetics in living cells and to measure the efflux activity of ATP BINDING CASSETTE TRANSPORTER, SUBFAMILY B, MEMBER 1 in both normal and malignant cells. (Leukemia 1997;11(7):1124-30). rhodamine 123(1+) : A cationic fluorescent dye derived from 9-phenylxanthene.		1.9710organic cation;
xanthene dye		fluorochrome
mitoguazone
Mitoguazone: Antineoplastic agent effective against myelogenous leukemia in experimental animals. Also acts as an inhibitor of animal S-adenosylmethionine decarboxylase.. mitoguazone : A hydrazone obtained by formal condensation of the two carbonyl groups of methylglyoxal with the primary amino groups of two molecules of aminoguanidine.		3.0710guanidines;
hydrazone		antineoplastic agent;
apoptosis inducer;
EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor
sulfur
Sulfur: An element that is a member of the chalcogen family. It has an atomic symbol S, atomic number 16, and atomic weight [32.059; 32.076]. It is found in the amino acids cysteine and methionine.		3.1130chalcogen;
nonmetal atom		macronutrient
cysteine
Cysteine: A thiol-containing non-essential amino acid that is oxidized to form CYSTINE.. L-cysteinium : The L-enantiomer of cysteinium.. cysteine : A sulfur-containing amino acid that is propanoic acid with an amino group at position 2 and a sulfanyl group at position 3.		2.7630cysteiniumfundamental metabolite
antimycin a
Antimycin A: An antibiotic substance produced by Streptomyces species. It inhibits mitochondrial respiration and may deplete cellular levels of ATP. Antimycin A1 has been used as a fungicide, insecticide, and miticide. (From Merck Index, 12th ed). antimycin A : A nine-membered bis-lactone having methyl substituents at the 2- and 6-positions, an n-hexyl substituent at the 8-position, an acyloxy substituent at the 7-position and an aroylamido substituent at the 3-position. It is produced by Streptomyces bacteria and has found commercial use as a fish poison.		1.9810amidobenzoic acid
echinomycin
Echinomycin: A cytotoxic polypeptide quinoxaline antibiotic isolated from Streptomyces echinatus that binds to DNA and inhibits RNA synthesis.		3.0710cyclodepsipeptide
warfarin
Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.		8.3611benzenes;
hydroxycoumarin;
methyl ketone
antimycin
[no description available]		1.9810
oligomycins
Oligomycins: A closely related group of toxic substances elaborated by various strains of Streptomyces. They are 26-membered macrolides with lactone moieties and double bonds and inhibit various ATPases, causing uncoupling of phosphorylation from mitochondrial respiration. Used as tools in cytochemistry. Some specific oligomycins are RUTAMYCIN, peliomycin, and botrycidin (formerly venturicidin X).		2.3820
ConditionIndicatedRelationship StrengthStudiesTrials
Adenocarcinoma, Basal Cell
[description not available]		06.4592
Diffuse Mixed Small and Large Cell Lymphoma
[description not available]		02.3820
Kahler Disease
[description not available]		01.9710
Adenocarcinoma
A malignant epithelial tumor with a glandular organization.		06.4592
Lymphoma, Non-Hodgkin
Any of a group of malignant tumors of lymphoid tissue that differ from HODGKIN DISEASE, being more heterogeneous with respect to malignant cell lineage, clinical course, prognosis, and therapy. The only common feature among these tumors is the absence of giant REED-STERNBERG CELLS, a characteristic of Hodgkin's disease.		02.3820
Multiple Myeloma
A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.		01.9710
EHS Tumor
[description not available]		01.9910
Cancer of Colon
[description not available]		04.1660
Cancer of Lung
[description not available]		04.6332
Cancer of Ovary
[description not available]		05.2143
Colonic Neoplasms
Tumors or cancer of the COLON.		04.1660
Lung Neoplasms
Tumors or cancer of the LUNG.		04.6332
Ovarian Neoplasms
Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.		05.2143
Anoxemia
[description not available]		02.4110
Malignant Melanoma
[description not available]		02.4110
Hypoxia
Sub-optimal OXYGEN levels in the ambient air of living organisms.		02.4110
Melanoma
A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445)		02.4110
Muscle Disorders
[description not available]		02.4110
Muscular Diseases
Acquired, familial, and congenital disorders of SKELETAL MUSCLE and SMOOTH MUSCLE.		02.4110
Cerebral Pseudosclerosis
[description not available]		02.610
Hepatolenticular Degeneration
A rare autosomal recessive disease characterized by the deposition of copper in the BRAIN; LIVER; CORNEA; and other organs. It is caused by defects in the ATP7B gene encoding copper-transporting ATPase 2 (EC 3.6.3.4), also known as the Wilson disease protein. The overload of copper inevitably leads to progressive liver and neurological dysfunction such as LIVER CIRRHOSIS; TREMOR; ATAXIA and intellectual deterioration. Hepatic dysfunction may precede neurologic dysfunction by several years.		02.610
Benign Neoplasms
[description not available]		07.5494
Neoplasms
New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.		07.5494
Cell Transformation, Neoplastic
Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill.		01.9810
Experimental Neoplasms
[description not available]		02.3920
Adenocarcinoma Of Kidney
[description not available]		04.3322
Cancer of Kidney
[description not available]		04.3322
Anemia
A reduction in the number of circulating ERYTHROCYTES or in the quantity of HEMOGLOBIN.		04.9733
Carcinoma, Renal Cell
A heterogeneous group of sporadic or hereditary carcinoma derived from cells of the KIDNEYS. There are several subtypes including the clear cells, the papillary, the chromophobe, the collecting duct, the spindle cells (sarcomatoid), or mixed cell-type carcinoma.		04.3322
Kidney Neoplasms
Tumors or cancers of the KIDNEY.		04.3322
Methemoglobinemia
The presence of methemoglobin in the blood, resulting in cyanosis. A small amount of methemoglobin is present in the blood normally, but injury or toxic agents convert a larger proportion of hemoglobin into methemoglobin, which does not function reversibly as an oxygen carrier. Methemoglobinemia may be due to a defect in the enzyme NADH methemoglobin reductase (an autosomal recessive trait) or to an abnormality in hemoglobin M (an autosomal dominant trait). (Dorland, 27th ed)		010.3853
Extravascular Hemolysis
[description not available]		03.3711
Hemolysis
The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.		03.3711
Cancer of Pancreas
[description not available]		01.9810
Pancreatic Neoplasms
Tumors or cancer of the PANCREAS. Depending on the types of ISLET CELLS present in the tumors, various hormones can be secreted: GLUCAGON from PANCREATIC ALPHA CELLS; INSULIN from PANCREATIC BETA CELLS; and SOMATOSTATIN from the SOMATOSTATIN-SECRETING CELLS. Most are malignant except the insulin-producing tumors (INSULINOMA).		01.9810
Carcinoma, Non-Small Cell Lung
[description not available]		03.3711
Carcinoma, Non-Small-Cell Lung
A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy.		03.3711
Breast Cancer
[description not available]		08.3711
Breast Neoplasms
Tumors or cancer of the human BREAST.		03.3711
Cancer of Esophagus
[description not available]		03.7721
Cancer of Stomach
[description not available]		03.3611
Esophageal Neoplasms
Tumors or cancer of the ESOPHAGUS.		03.7721
Stomach Neoplasms
Tumors or cancer of the STOMACH.		03.3611
Carcinoma, Anaplastic
[description not available]		04.3322
Carcinoma
A malignant neoplasm made up of epithelial cells tending to infiltrate the surrounding tissues and give rise to metastases. It is a histological type of neoplasm and not a synonym for cancer.		04.3322
Recrudescence
[description not available]		03.3611
Deficiency, Factor II
[description not available]		03.3611
Experimental Mammary Neoplasms
[description not available]		01.9710
Germinoblastoma
[description not available]		01.9710
Colorectal Cancer
[description not available]		01.9710
Lymphoma
A general term for various neoplastic diseases of the lymphoid tissue.		01.9710
Colorectal Neoplasms
Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI.		01.9710
Rhabdomyosarcoma
A malignant solid tumor arising from mesenchymal tissues which normally differentiate to form striated muscle. It can occur in a wide variety of sites. It is divided into four distinct types: pleomorphic, predominantly in male adults; alveolar (RHABDOMYOSARCOMA, ALVEOLAR), mainly in adolescents and young adults; embryonal (RHABDOMYOSARCOMA, EMBRYONAL), predominantly in infants and children; and botryoidal, also in young children. It is one of the most frequently occurring soft tissue sarcomas and the most common in children under 15. (From Dorland, 27th ed; Holland et al., Cancer Medicine, 3d ed, p2186; DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, pp1647-9)		01.9710